CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 14 enrolled
Drug / intervention
Armodafinil +3 moredrug
Likely dose
Armodafinil 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01317550
NCT01317550N/ACompleted
CompareCT.gov

A Pilot Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer

M.D. Anderson Cancer Center·interventional·Posted Mar 17, 2011·Updated Feb 10, 2020

In Brief

A clinical study evaluating Armodafinil, Placebo, and 2 other interventions for Lung Cancer. Completed, enrolled 14 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to compare armodafinil and minocycline when given alone or in combination to learn which is better for controlling symptoms, such as the side effects of chemoradiation, when given to treat lung cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 17, 2011
Enrollment StartJul 1, 2011
Primary CompletionFeb 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 15.3 years ago

Interventions

Armodafinildrug

150 mg by mouth once a day for a 10 week cycle.

Placeboother

Capsules taken by mouth once a day for a 10 week cycle.

Minocyclinedrug

100 mg by mouth twice a day for a 10 week cycle.

Questionnairesbehavioral

Completion of symptom questionnaire before chemoradiation, then once a week during Weeks 1-16, takes up to 5 minutes to complete.